Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $47.7 million.

  • Tango Therapeutics' Cash from Financing Activities rose 5.79% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 91.50%. This contributed to the annual value of $47.7 million for FY2024, which is 42.16% down from last year.
  • Tango Therapeutics' Cash from Financing Activities amounted to $47.7 million in FY2024, which was down 42.16% from $82.4 million recorded in FY2023.
  • Over the past 5 years, Tango Therapeutics' Cash from Financing Activities peaked at $357.3 million during FY2021, and registered a low of $1.6 million during FY2022.
  • For the 3-year period, Tango Therapeutics' Cash from Financing Activities averaged around $43.9 million, with its median value being $47.7 million (2024).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first slumped by 99.55% in 2022, then surged by 5,002.54% in 2023.
  • Over the past 5 years, Tango Therapeutics' Cash from Financing Activities (Yearly) stood at $80.9 million in 2020, then soared by 341.77% to $357.3 million in 2021, then plummeted by 99.55% to $1.6 million in 2022, then surged by 5,002.54% to $82.4 million in 2023, then crashed by 42.16% to $47.7 million in 2024.